Anacor Pharmaceuticals, Inc. to Present New Data on AN2728 and GSK ‘052 at Upcoming Meetings

PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that it will present data on two of its compounds at the following conferences:

“Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis” * 2011 Society for Investigative Dermatology (SID) Annual Meeting o Lee Zane, M.D., Anacor’s Chief Medical Officer, will present “Safety and efficacy of AN2728 ointment in a phase 2b dose-ranging bilateral study of mild-to-moderate plaque psoriasis” in a poster session on Thursday May 5, 2011 at 10 a.m. MT / 9 a.m. PT. * 21st European Congress of Clinical Microbiology and Infectious Diseases o Liang Liu, Senior Director of Pharmacokinetics and Drug Metabolism, will present “Interspecies scaling for prediction of human intravenous pharmacokinetics of GSK2251052 (GSK ‘052), a novel boron-based antimicrobial against Gram-negative bacteria” in poster topic 17 on Saturday May 7, 2011 at 3:30 p.m. CET / 6:30 a.m. PT. o Dr. Zane will present “Safety, tolerability, and pharmacokinetics of a novel Gram-negative antimicrobial, GSK2251052 (GSK ‘052), in healthy subjects” in poster topic 65 on Monday May 9, 2011 at 12:30 p.m. CET / 3:30 a.m. PT.